{"entity":{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","aka":[],"tldr":"Mariana Oncology designs small protein fragments that carry a radioactive isotope to tumours, starting with small cell lung cancer. Novartis bought the company in 2024 for 1 billion dollars up front.","summary":"Mariana Oncology, founded in 2021 in Watertown, Massachusetts by Atlas Venture, Access Biotechnology and RA Capital Management, built a fully integrated radiopharmaceutical platform combining peptide discovery, radiochemistry, in-house GMP manufacturing, isotope supply and formulations to extend product shelf life. Its portfolio of peptide-based radioligand therapies addresses a range of solid tumours; the lead candidate MC-339 is a radioligand therapy for small cell lung cancer that was expected to enter the clinic in 2024. The company closed a USD 175 million Series B in September 2023 co-led by Deep Track Capital and Forbion, and in May 2024 agreed to be acquired by Novartis for USD 1 billion upfront and up to USD 750 million in milestones. As a Novartis company it announced a USD 50 million expansion of radioligand R&D facilities in June 2025.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://marianaoncology.com/"},{"label":"Series B press release","url":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/"},{"label":"Novartis acquisition announcement","url":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/"}],"tags":[],"related":[],"cancers":["sclc"],"sections":["radiopharma"],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["MC-339 target not stated on fetched pages. Series A not fetched and omitted."],"hq":"Watertown, MA","country":"US","companyType":"radiopharma","website":"https://marianaoncology.com/","founded":2021,"stage":"acquired","investors":["atlas-venture","ra-capital","forbion"],"funding":[{"round":"Series B","year":2023,"amountUsd":175000000,"source":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/"},{"round":"Acquisition","year":2024,"amountUsd":1000000000,"source":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/","note":"USD 1 billion upfront plus up to USD 750 million in milestones"}],"acquiredBy":"novartis"},"route":"/companies/mariana-oncology/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"company":[{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/"},{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}]}}